Targocil
产品说明书
 |
同义名 : | - |
| CAS号 : | 1200443-21-5 | |
| 货号 : | A377477 | |
| 分子式 : | C21H22ClN5O4S | |
| 纯度 : | 98%+ | |
| 分子量 : | 475.95 | |
| MDL号 : | MFCD19441262 | |
| 存储条件： |
Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 35 mg/mL(73.54 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA. MICs of Targocil against S. aureus strains Newman, MW2, MG2375, and MG2389 are 1 μg/mL for all strains. Targocil shows excellent activity against S. aureus isolates from suspected cases of bacterial keratitis, including both MSSA and MRSA isolates, with MICs that range from 1 to 2 μg/ mL. Targocil activity was moderately sensitive to the presence of serum, but it inhibited extracellular and intracellular bacteria in the presence of HCECs (human corneal epithelial cells) better than vancomycin. Targocil-resistant strains exhibited a significantly reduced ability to adhere to HCECs[1]. Targocil inhibited intracellular bacteria in the presence of human corneal epithelial cells to a greater extent than vancomycin. Targocil-resistant strains exhibited a significantly reduced ability to adhere to human corneal epithelial cells[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.10mL 0.42mL 0.21mL |
10.51mL 2.10mL 1.05mL |
21.01mL 4.20mL 2.10mL |
| 参考文献 |
|---|